University Hospital Zurich and University Inselspital Berne implant their first patients with Sequana Medical’s ALFApump® System
Zurich, Switzerland: 24 May 2012 - Zürich-based company Sequana Medical reported that Switzerland's first patients have received the ALFApump® System. The ALFApump® System is a fully implantable pump system designed to remove excess abdominal fluid, known as ascites, that collects in patients suffering from advanced chronic liver disease.
"This innovative technology provides us with a new and completely different treatment option for patients with refractory ascites," commented Professor Beat Müllhaupt, University Hospital Zurich, Department for Gastroenterology and Hepatology. "Up to now the only options for these patients were repeated paracentesis, insertion of a TIPS with its associated side effects, or liver transplantation".
Next > Nexstim announces FDA clearance for NexSpeech® – enabling noninvasive speech mapping prior to neurosurgery
Previous > EpiGaN starts production on Research Campus Hasselt